Bevacizumab Dose Affects the Severity of Adverse Events in Gynecologic Malignancies

In conclusion, this study revealed different types of adverse events and higher cumulative incidences than those reported in previous clinical trials that tested bevacizumab for treating gynecological malignancies. Moreover, we observed that bevacizumab had cumulative and plateau effects on hypertension and proteinuria events. Ethics Statement This study was approved by the Research Ethics Committee at the National Taiwan University Hospital (201706023RINC). All of the patients’ data were fully anonymized before we accessed them and the Research Ethics Committee waived the requirement for informed consent. Author Contributions S-PL and W-FC conceived and designed the study. S-PL, H-CH, Y-JT, Y-LC, and Y-CC performed acquisition of data. S-PL, H-CH, Y-JT, and W-FC analyzed and interpreted the data. S-PL and W-FC drafted the manuscript. C-AC critically revised the manuscript. Conflict of Interest Statement The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.[extraconflict] References Aghajanian, C., Blank, S. V., Goff, B. A., Judson, P. L., Teneriello, M. G., Husain, A., et al. (2012). OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J. Clin. Oncol. 30, 2039–204...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research